Capacity Shortages Unlikely To Hold Back Cell And Gene Therapies
The pharmaceutical industry's manufacturing capacity for cell and gene therapies is under pressure from an ever-increasing number of life sciences companies wanting to exploit rare expertise in the sector, but CMOs and government-backed facilities are rapidly coming on-stream, hoping to develop local clusters of companies to deliver the complete "living medicines" supply chain.
You may also be interested in...
Scale-up in particular is a challenge and FDA wants to help lower the barrier, CBER Director Peter Marks tells rare disease conference.
Udit Batra, member of Merck KGaA's executive board and CEO, life science, tells Scrip in an interview how the company is building on its play in the hot gene therapy area. Batra also outlines how the life science unit’s industry leading e-commerce platform already has the performance "of the level of Amazon or Alibaba" for the scientific space.
Lilly’s migraine prevention therapy, galcanezumab, is among the nine new products that companies have submitted to the European Medicines Agency for evaluation in recent weeks.